-
Regulatory June 5, 2023 EnglishInitiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction
-
Non Regulatory May 30, 2023 EnglishInitiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine
Share
Initiator Pharma Numbers
-
Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
-
Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
-
Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiator Pharma currently has a portfolio of four projects, of which two are in clinical development and two are in preclinical development.
CEO letter
2023 has started in the same positive spirit as we ended 2022. Our ongoing clinical programs are progressing according to plan and during the year we look forward to presenting results for both of our main clinical stage assets; IP2018 in development for psychogenic erectile dysfunction and depression and Pudafensine in development for organic erectile dysfunction and neuropathic pain.
